Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin’s lymphoma: an observational study using SEER population-based data

• Yue Yang,
• Shang Li,
• Xiao Zhu,
• Yi Kong,
• Mingtao Zhang,
• Xiangping Liang,
• Zherui Zhang,
• Shuzhen Tan,
• Yingqi Li,
• Yueyuan Zhong,
• Yingqi Shao,
• Jiayi Xu,
• Zesong Li

Affiliations

Yue Yang

2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China

Shang Li

2 Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore

Xiao Zhu

1Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Denver AMC, Aurora, Colorado, USA

Yi Kong

1Institute of Pathology, University Hospital of Cologne, Cologne, Germany

Mingtao Zhang

2 The People’s Hospital in Altay Region, Xinjiang, China

Xiangping Liang

School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, People`s Republic of China

Zherui Zhang

School of Laboratory and Biotechnology, Southern Medical University, Guangzhou, People`s Republic of China

Shuzhen Tan

Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People`s Republic of China

Yingqi Li

Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People`s Republic of China

Yueyuan Zhong

Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People`s Republic of China

Yingqi Shao

Computational Oncology Laboratory, Guangdong Medical University, Zhanjiang, People`s Republic of China

Jiayi Xu

School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People`s Republic of China

Zesong Li

Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People`s Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, People`s Republic of China